This clinical trial, sponsored by St. Jude Children's Research Hospital, focuses on a novel approach to hematopoietic cell transplantation (HCT) for high-risk hematologic malignancies in pediatric and young adult patients. The use of TCRαβ-depleted progenitor cells combined with additional memory T-cell donor lymphocyte infusion (DLI) and the incorporation of blinatumomab presents a differentiated therapeutic strategy that may enhance engraftment and reduce the incidence of graft-versus-host disease (GVHD). The target patient population is significant, given the high unmet need in pediatric oncology, particularly for those lacking suitable HLA-matched donors. The potential for improved outcomes could position this therapy favorably against existing HCT protocols and CAR-T therapies, which are currently gaining traction in the market. The trial's results could influence future treatment guidelines and establish a competitive edge in the pediatric oncology space.